Takeda Pharmaceutical Company Limited announced the start of Phase 2/3 and Phase 3 clinical trials of rasagiline (generic name, development code: TVP-1012), an investigational compound for the treatment of Parkinson's disease, in Japan. The main portion of clinical trials started this time aiming to examine efficacy and safety of rasagiline consists of a couple of multicenter, randomized, double-blind and placebo-controlled parallel-group comparative trials. One is a Phase 2/3 clinical trial conducted with the Japanese patients with Parkinson's disease under the treatment with levodopa (adjunctive therapy study), and its primary endpoint is change of mean total daily off-time.

Another is a Phase 3 clinical trial conducted with the Japanese patients with early stage Parkinson's disease (monotherapy study), and its primary endpoint is sum of Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts 2 and 3 scores.